Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
toripalimab + nab-paclitaxel + gemcitabine
- Development stage
- Unknown
- Lead developer
- Junshi Biosciences
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Toripalimab + nab-paclitaxel + gemcitabine is a combination chemo-immunotherapy regimen being investigated for the treatment of pancreatic cancer. Toripalimab (JS001) is a humanized IgG4 monoclonal antibody developed by Junshi Biosciences that targets the programmed cell death protein 1 (PD-1) receptor, preventing its interaction with PD-L1 and PD-L2 to restore anti-tumor immunity. Nab-paclitaxel (Abraxane) is an albumin-bound nanoparticle formulation of paclitaxel that promotes microtubule assembly and inhibits disassembly, leading to mitotic arrest. Gemcitabine is a pyrimidine nucleoside analog that inhibits DNA synthesis. This specific triplet combination is being evaluated by Fudan University in a Phase II clinical trial (NCT04412408) in conjunction with PULSAR (Personalized Ultra-fractionated Stereotactic Adaptive Radiotherapy) for patients with locally advanced unresectable or recurrent pancreatic ductal adenocarcinoma (PDAC).
- Brand names
- TuoyiAbraxaneGemzar
- Other names
- PD-1 antibodyPD1 antibodyPD 1 antibodyalbumin-bound paclitaxelPD-1 combined with Nab-paclitaxel/Gemcitabine
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on toripalimab + nab-paclitaxel + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on toripalimab + nab-paclitaxel + gemcitabine.